Survival outcomes, digital TILs and on-treatment PET/CT during neoadjuvant therapy for HER2-positive breast cancer: results from the randomized PREDIX HER2 trial.
Alexios MatikasHemming JohanssonPer GrybäckJudith BjöhleBalazs AcsCeren BoyaciTobias LekbergHanna FredholmEllinor ElinderSara MargolinErika Isaksson-FrimanAna BoschHenrik LindmanJamila ArdaAnne AnderssonSusanne AgartzMats HellströmIoannis ZerdesJohan HartmanJonas BerghThomas HatschekTheodoros FoukakisPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Long-term outcomes following neoadjuvant T-DM1 were similar to neoadjuvant THP. SUVmax after two cycles of neoadjuvant therapy for HER2-positive breast cancer may be an independent predictor of both short- and long-term outcomes. Combined assessment with TILs may facilitate early selection of poor responders for alternative treatment strategies.